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Chronic hepatitis C virus infection represents an insidious disease that is often 
detected with signs of liver cirrhosis or hepatocellular carcinoma. It is practicaly 
impossible to achieve a significant therapeutic progress in these patients without 
performing a liver transplantation. However, due to underdeveloped program of organ 
donations, this kind of intervention, as the last helpful procedure, is often not realized.  
This study presents three patients (out of 121 treated patients) followed during a 
two-year period. The patients had been initially registered when the stage of their 
disease became severe: liver failure with signs of decompensation. Antiviral therapy 
(pegylated interferon and ribavirin) in these patients have no use, hence only a 
corrective therapy is administered. Pathohistological findings in two patients revealed 
hepatocellular carcinoma, and in one case lethal outcome was the result of severe 
hepatic decompensation, hepatopulmonary and hepatorenal syndromes, as well as 
developed cardiopulmonary failure. Lethal outcome occurred in the period of 2 to 14 
months after the first visit to a doctor. One patient was on the list for liver 
transplantation; however, surgery was not performed and soon after a fatal outcome 
ensued. Acta Medica Medianae 2011;50(2):49-52. 
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Introduction  
 
Hepatitis C virus infection (HCV) is a 
progressive disease that has a high rate of 
morbidity and significant mortality. It is estimated 
that the number of persons with the infection 
represents approximately 3% of the world 
population at present, or 170-200 million cases 
(1,2). The number of the infected is increasing, 
each year by 3-4 million new patients (3). In 
85% of chronically infected persons there are 
conditions that can lead to a disease progression 
into liver cirrhosis and hepatocellular carcinoma 
(2,4-6). At the same time, most patients with 
chronic HCV infection are candidates for liver 
transplantation (2,7,8). Therapeutic response in 
these patients greatly depends on the virus 
genotype. Namely, genotypes 1 and 4 cause a 
lower percentage of therapy response (50-55%) 
than genotypes 2 and 3 (80%). Unfortunately, 
the most common virus genotype in Europe is 
genotype 1, with subtypes 1a and 1b. The number 
of infected people in Serbia is between 100-150 
thousands. As for the genetic background of our 
country, there is an identical genotype background 
as on the territory of the Mediterranean, which is 
dominated by virus genotype 1 (8). It should be 
noted that disease is not equally widespread in 
the population. It is particularly frequent among 
drug users, hemophiliacs and patients on hemo-
dialysis (10,11). Disease evolution significantly 
depends on the virus genotype, timely recognition 
of disease and therapeutic approach to patients. 
The disease course is asymptomatic and very 
often is registered in advanced stage when the 
therapeutic approach is very inefficient due to 
already developed irreversible changes in the 
liver and other organs.  
Hepatitis C is a systemic disease that may 
appear in a wide spectrum of clinical manifesta-
tions. Generalized signs and symptoms of chronic 
HCV infection include: fatigue, joint pain, itching, 
sleeping disturbance, changes in appetite, nausea 
and depression. In patients with liver cirrhosis, 
the liver function is impaired and can develope 
portal hypertension, ascites, spontaneous nose 
and gums bleeds, jaundice and the syndrome of 
cognitive impairment. Also, there are associated, 
the „so-called“ extrahepatic manifestations of 
chronic hepatitis C infection (12-14). The presence 
of co-infection (HBV, HIV, etc.) or some comorbid 
condition (alcohol abuse, toxicomania) significantly 
accelerates disease progression, leading to a fatal 
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outcome (15,16). Contemporary therapeutic 
approach to chronic HCV infection consists of 
pegylated interferon application once a week, 
administrated by subcutaneous injections and 
daily ribavirin intake (1,3,11). Because of the 
relative ineffecti-veness of the therapy and 
presence of non-responders and relapsers, a 
triple therapy is supported in the world today. 
This therapy includes the use of HCV protease and 
polymerase inhibitors, beside the aforementioned 
medications (17). 
 
Aim of the study, patients and methods 
 
The work presents three patients in whom 
the diagnosis of hepatitis C infection was set at 
the time the disease took a fatal course. Out of 
121 patients tested and treated during the two 
years of observations (2009-2010), three cases 
were selected. They had a fast-evolving disease 
course, which from the time of establishing the 
diagnosis rapidly led to death. Diagnosis of the 
disease was carried out with conventional testing 
methods: clinical examination, laboratory tests, 
serologic tests, histopathological examinations 
and PCR HCV-RNA and genotyping method. The 
aim of the study was to determine potential 
comorbid conditions or the presence of co-
infections that might influenced such evolutionary 
end of the disease. At the same time, patients’ 
age and gender characteristics were observed as 
well as a genotypic background of hepatitis C 
virus. 
 
Results 
 
Patient M.M., protocol number 2962/08, 
was born in 1938 and was retired. The patient 
was first seen at the end of 2008. At the first 
examination the patients’ findings were suspected 
for advanced stage of liver disease and the 
diagnosis of liver cirrhosis was set. Organomegaly 
was observed (the liver was palpable at 1-2 cm 
below the costal arch, with sharp edge, uneven 
surface, slightly tender to palpation; spleen was 
enlarged by approximately 2-3 cm). Additionally 
to these findings, palmar erythema was registered 
in the patient, together with the presence of varices 
during abdominal examination. The patient was 
well nourished, in good mood and ready for 
cooperation, willing to receive medical assistance. 
Heteroanamnestic data excluded alcohol consump-
tion. Among performed laboratory tests, the 
following abnormal values emphasized: erythrocytes 
sedimentation rate (51/77), low platelet count 
(44*109/L), high levels of alpha-fetoprotein (12 
times increased, 121.72 ng/mL). Alkaline phospha-
tase value (ALP) and gamma-glutamyl trans-
peptidase (gamma-GT) differed from normal 
values. Total bilirubin was 34.6 mmol/L with 
simultaneously mild aminotransferase elevation, 
aspartate aminotransferase (AST) 54 U/L and the 
values of alanine aminotransferase (ALT) were 
normal (34 U/L). Albumin level was 32 g/L and 
prothrombin time 54%. An ultrasound finding of 
the upper abdomen was in correlation with 
clinically verified organomegaly, without the 
presence of ascites. In further examination, the 
presence of HCV antibodies was verified in the 
patient, while HBsAg and AtHIV were negative. 
Analysis by PCR method proved the presence of 
HCV-RNA, with 11.196.000 viral copies, as well 
the virus genotype 1. Follow-up of the patient 
showed a progressive body weight reduction and 
the appearance of dull pain at the right and left 
costal arch. A multislice computed tomography 
(MSCT) of the liver was performed, in which a 
tissue change was observed, pointing to possible 
infiltrations or intensive liver repair. A sample of 
alterated hepatic tissue was taken with targeted 
liver biopsy. The result of pathological examination 
of the sampled material indicated a primary liver 
hepatocellular cancer. Exitus letalis occurred within 
one year from the initial contact with the patient. 
Patient R.Lj., protocol number 958/10, born 
in 1952, was employed as a clerk. She was 
hospitalized during her first visit to a physician 
due to severe malaise, loss of appetite, yellowish 
staining of eyes and skin, palmar erythema and a 
large number of spider nevi on the chest, face 
and hands. Urine discoloration was also reported. 
Further clinical examination of the patient 
revealed enlarged liver, 2 cm below the costal arch, 
and the spleen was palpable on the left costal 
arch. She was admitted with the diagnosis of liver 
cirrhosis. After hospital admission, the patient 
underwent a series of analysis: erythrocyte 
sedimentation rate 80/90, platelet count (148* 
109/L) was relatively within the normal range, 
AST 142 U/L, ALT 321 U/L, gamma-GT 600 U/L, 
ALP 520 U/L, alpha-fetoprotein 35.35 ng/ml with 
positive AtHCV finding. Analyses of HIV antibodies 
and HBsAg were negative. There was no data of 
alcohol consumption. During hospitalization, progre-
ssion of bilirubin values (680 mmol/L) was 
observed. Paraclinical tests were started, so the 
patient underwent an echo of the upper abdomen, 
CT of the liver and liver MSCT. During the tests, 
infiltrative changes in the right and left liver lobe 
were determined. A targeted biopsy of determined 
changes was performed, with three samples 
taken. Polymerase chain reaction on HCV-RNA 
was positive but genotyping was not done. Exitus 
letalis occurred two months after the initial 
contact with the physician, with the signs of 
hemorrhagic syndrome. Histopathological findings 
of the taken samples indicated hepatocellular 
carcinoma. 
Patient M.S., protocol number 3405/8, was 
born in 1953 and was a sociologist by profession. 
The patient was hospitalized with the signs of 
weakness, poor urination, sudden increase in the 
abdomen girth, churning in the stomach, 
nosebleed and a weakened breathing on the right 
side of the chest. The diagnosis on admission was 
liver cirrhosis. Complete laboratory analysis showed 
mild aminotransferase increase AST 62 U/L, ALT 58 
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values, alkaline phosphatase and gamma-GT 
showed no change compared to the normal 
range. Albumins were decreased (23.1 U/L), as 
well as the value of total protein (54 g/L) and 
prothrombotic time (28s), while the alpha-
fetoprotein level was slightly above the normal 
values, or 11.93 U/L. In the course of further 
examination, pulmonary roentgenography was 
performed when pleural effusion was detected on 
the right side. Because of compromised breathing, 
a pleural puncture was repeatedly performed, 
with release of large amount of fluid, over one 
liter. Echo examination of the upper abdomen 
showed a small liver floating in ascites and 
enlarged spleen (145 mm). Antibodies to HCV 
were detected. Performed PCR HCV-RNA was 
positive for the virus genotype 1. Judging by her 
attitudes, the patient did not initially seem to 
take the illness seriously. After the liver 
compensation, the patient was followed in an 
outpatient care unit and a liver transplantation 
was proposed. For that reason the patient was 
sent for a second opinion in the Clinical Center in 
Belgrade, Department of Hepatology, where she 
was put on the waiting list for liver trans-
plantation. The first liver transplantation attempt 
was not performed because of graft damage. In 
the meantime, the patient redeveloped the 
symptoms of hepatopulmonary and hepatorenal 
syndromes. In addition to these problems, the 
patient became encephalopatic, the signs of 
cardiac weakness also appeared, after which she 
was hospitalized in cardiology unit, where the 
lethal outcome occurred. 
 
Discussion   
 
Presented patients were hospitalized for the 
first time with the signs not clearly indicative of 
chronic hepatitis C infection. Hepatitis C infection 
is difficult to determine because of its insidious 
course, so that patients can have it in their 
organism for many years (11,12). During this 
time, in certain percentage of patients (65 to 
80%), HCV infection progresses causing different 
degree of liver damage, and in the worst cases 
even cirrhosis or liver cancer. Frequently, patients 
visit a physician after the signs of decompensated 
disease have already occurred (jaundice). Some-
times, patients are monitored under different 
diagnoses, because of gallbladder ultrasound 
findings, without further analysis of registered 
problems (11-13). 
Hepatitis C infection alone can have in its 
progression some supportive factors, in the form 
of other infectious agents’ presence (hepatitis B 
or HIV) or other hepatotoxic substances (alcohol, 
corticosteroids use and others) (10). The observed  
patients had no other factors associated with 
progression of hepatitis virus infection. The 
disease is likely to have lasted for a long period 
o f  t i m e ,  f r o m  l 5  t o  2 0  y e a r s ,  p e r h a p s  l o n g e r .  
During this time, patients had no knowledge of 
the infection presence. Upon hospital admission, 
chronic HCV infection was verified, but the 
applied therapy did not have an etiological 
character, only corrective one due to advanced 
disease stage. Implemented correction measures 
were complex. They were directed to the disease 
compensation (albumins intake, careful diuretics 
intake), struggle with threatening encephalopathy 
(diet, L-ornithine, L-aspartate, eubiotics intake, 
intestinal sterilization with antibiotics, enemas, 
etc.), and correction of hemorrhagic syndrome 
(plasma infusions, coagulation factors, platelets). 
Due to development of hepatopulmonary syndrome 
and compromised respiration with massive pleural 
effusion in one patient, pleural punction was 
repeatedly done. 
The situation in these patients is significantly 
complicated because of poorly organised organ 
donation program and the lack of liver transplan-
tation services. Liver transplantation, as the only 
option in these situations, usually comes down to 
pondering, and patients rarely, for the lack of 
time, reach this life-saving intervention (7).  
Rapid fatal outcome in these patients with 
chronic HCV infection imposes the need for 
disease recognition as early as possible, so that 
therapeutic attempts could be made in order to 
preclude lethal outcomes. Also, in patients with 
liver transplantation indication, transplantation 
should be performed as soon as possible. 
 
Conclusion 
 
The three presented patients had the first 
contact with an infectologist as the most 
competent expert in managing HCV infection in 
terminal stage of the disease. Etiological treatment 
was not successful in the treatment of these patients 
(pegylated interferon plus ribavirin). In two patients, 
exitus letalis resulted from hepatitis C infection 
complications or the presence of hepatocellular 
carcinoma. In one patient, the life-threatening 
complaints, at one moment of the disease 
evolution, originated from pleural effusion. Liver 
transplantation was not undertaken in one 
patient, although pretransplantation preparations 
were already started. Also, our patients did not 
show the presence of co-morbid conditions. 
These findings impose a need for active 
HCV infection search in the so-called non-risk 
groups, as potential patients get the chance to be 
treated according to contemporary recommen-
dations.  
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SUDBINA BOLESNIKA SA KASNO OTKRIVENOM HEPATITIS C 
INFEKCIJOM - PRIKAZ BOLESNIKA 
 
Velimir Kostić, Aleksandar Petrović, Jelena Radović, Jovana Kostić, Stevan Vujić, Branislav Jovanović i 
Lidija Popović 
 
  Hronični virusni hepatitis C predstavlja podmuklu bolest koja se često otkriva u 
vreme prisutnih promena, tipa ciroze jetre ili hepatocelularnog karcinoma. Kod ovih 
bolesnika praktično ne može biti učinjen značajan terapijski pomak, izuzev realizovanja 
transplantacije jetre. Međutim, zbog nedovoljno razvijenog donatorstva organa, ovakva 
intvencija, kao poslednji spasonosni zahvat, često se ne realizuje. 
U radu su prikazana tri bolesnika (od 121-og lečenog bolesnika) praćena tokom 
dvogodišnjeg perioda. Bolesnici su prvi put registrovani kada je njihova bolest imala 
težak stepen: insuficijenciju jetre sa znacima dekompenzacije. Antivirusna terapija 
(pegilovanim interferonom i ribavirinom) kod ovakvih bolesnika nema primenu, te je 
samo sprovođena korektivna terapija. Kod dva bolesnika je patohistološkom obradom 
dokazno prisustvo hepatocelularnog karcinoma, dok je kod jedne bolesnice smrtni ishod 
nastao usled teške dekompenzacije jetre, pojave hepatopulmonalnog i hepatorenalnog 
sindroma i razvoja kardiopulmonalne slabosti. Smrtni ishod je kod bolesnika nastupio u 
periodu od dva do 14 meseci od momenta prvog susreta. Jedna od prikaznih bolesnica 
bila je na listi za transplantaciju jetre, međutim, operacija nije izvedena i nedugo zatim 
usledio je smrtni ishod.  Acta Medica Medianae 2011;50(2):49-52. 
 
Ključne reči: hronični hepatitis C, ciroza jetre, hepatocelularni karcinom, antivirusna 
terapija 